Streamex Corp. current report, 18 August 2017

Full document

Business Context and Reporting Period

This Form 8-K is filed by BioSig Technologies, Inc. (not Streamex Corp.) on August 18, 2017. The report details the consummation of the seventh closing under a Unit Purchase Agreement dated April 6, 2017. The company is identified as an Emerging Growth Company.

Key Financial Metrics

The filing reports a specific capital raise event rather than periodic financial performance metrics (revenue, profit, cash flow, or margins are not provided in this document).

  • Transaction Date: August 18, 2017
  • Units Issued: 351,000 Units
  • Total Consideration Raised: $526,500
  • Price Per Unit: $1.50
  • Unit Composition: 1 share of Common Stock + 1 warrant to purchase 0.5 shares of Common Stock.
  • Warrant Exercise Price: $1.50 per share.

Material Changes and Historical Context

This transaction represents the seventh closing under the Purchase Agreement. The filing provides a summary of previous closings under the same agreement:

  • First Closing (April 6, 2017): 426,667 Units for $640,000.
  • Second through Fifth Closings (April–June 2017): 399,933 Units for $599,898.
  • Sixth Closing (July 13, 2017): 267,002 Units for $400,500.

Each investor in the August closing also became a party to the Registration Rights Agreement dated April 6, 2017.

Guidance, Risks, and Unusual Items

Regulatory Status: The securities were not registered under the Securities Act of 1933. They were offered and sold in reliance on the exemption from registration under Section 4(a)(2) and Regulation D (Rule 506). All investors represented they were accredited investors.

Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding future operations or financial performance beyond the execution of the purchase agreement.

Investor Verification Checklist

  • Verify the total aggregate capital raised under the Unit Purchase Agreement across all seven closings.
  • Confirm the total number of shares and warrants outstanding post-transaction.
  • Review the Registration Rights Agreement to understand future liquidity options for these investors.
  • Check subsequent filings for the company's use of the $526,500 raised in this specific closing.